About DNA
Our Mission

DNA, Inc. is a leading biotechnology company using human genetic information to develop, manufacture and market pharmaceuticals that address significant unmet medical needs. DNA commits itself to the highest standards of integrity in contributing to the best interests of patients, the medical profession and its employees, and to seeking significant returns to its stockholders based on the continued pursuit of excellent science. The company has one of it's headquarters in St. Louis and is traded on the New York Stock Exchange under the symbol DNA.

Our Products

Fourteen of the approved products in biotechnology stem from DNA science. DNA manufactures and markets nine products in the United States:

• Herceptin® (Trastuzumab) for first line therapy in combination with paclitaxel and as a single agent in second and third line therapy for patients with metastatic breast cancer who have tumors that overexpress the HER2 (human epidermal growth factor receptor2) protein;
  
  
• Rituxan® (Rituximab) for the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin's lymphoma;
  
  
• TNKase™ (Tenecteplase), a single-dose clot-busting agent for the treatment of acute myocardial infarction (heart attack);
  
  
• Activase® (Alteplase, recombinant), a tissue-plasminogen activator to dissolve blood clots, for treating patients with acute myocardial infarction, patients with acute massive pulmonary embolism (blood clots in the lungs), and for treating patients with acute ischemic stroke (brain attack) within the first three hours of symptom onset;
  
  
• Nutropin Depot™ [somatropin (rDNA origin) for injectable suspension], a sustained release formulation of growth hormone for the treatment of growth hormone deficiency (GHD) in children;
  
  
• Nutropin AQ® [somatropin (rDNA origin) injection], a liquid formulation of Nutropin for the same indications as Nutropin®;
  
  
• Nutropin® [somatropin (rDNA origin) for injection] human growth hormone for treating GHD, for treating growth failure due to chronic renal insufficiency prior to kidney transplantation, and for treating short stature associated with Turner syndrome;
  
  
• Protropin® (somatrem for injection) growth hormone also for the treatment of GHD in children;
  
  
• Pulmozyme® (dornase alfa, recombinant) Inhalation Solution, the first new therapeutic approach for cystic fibrosis in more than 30 years.
  
  

The Patient Assistance Program

Through its long-standing Patient Assistance Program, DNA assures that everyone who needs these important medicines can get them. DNA also supports the continuing improvement of patient care through its post-marketing studies, which collect data on the health progress of patients who use DNA medicines nationwide.